Rheumatoid arthritis and cardiovascular disease: an update on treatment issues

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Rheumatoid arthritis (RA) is associated with a significantly elevated risk of cardiovascular disease (CVD).
• Both traditional CVD risk factors and chronic inflammation inherent in RA contribute to this heightened risk.
• Existing evidence highlights the complex interplay between RA, its treatments, and cardiovascular health.

Purpose of the Study:

• To review treatment thresholds for traditional cardiovascular disease (CVD) risk factors in rheumatoid arthritis (RA) patients.
• To evaluate whether RA-specific treatments influence the modulation of cardiovascular risk.
• To synthesize current evidence on managing CVD risk in the context of RA.

Main Methods:

• Systematic review of existing epidemiologic studies and clinical data.
• Analysis of data on traditional CVD risk factors and their management in RA.
• Examination of the impact of RA-specific therapies, including biologic disease-modifying anti-rheumatic drugs (DMARDs), on CVD outcomes.

Main Results:

• Substantial data confirm increased CVD risk in RA patients.
• Both traditional risk factors and inflammation are key contributors to CVD in RA.
• Epidemiologic studies suggest that aggressive immunosuppression with biologic DMARDs, like TNF antagonists, may reduce CVD events.
• No randomized controlled trials (RCTs) specifically addressing CVD management in RA have been published.

Conclusions:

• Accumulating epidemiologic evidence supports a link between traditional CVD risk factors, RA treatments, and cardiovascular outcomes.
• The current evidence base necessitates further investigation through randomized controlled trials (RCTs).
• RCTs are crucial for establishing definitive management strategies for cardiovascular risk in RA patients.